Decoding the Dilemma: A Comprehensive Approach to Diagnosing and Managing Elevated Liver Enzymes in Clinical Practice
OthersPage Navigation
Introduction
Elevated Liver Enzymes (ELE) often present a diagnostic challenge for clinicians due to the myriad of potential causes. This brief review aims to provide a comprehensive approach to the diagnosis and management of ELE.
Diagnosis
Diagnosis of ELE begins with a thorough history and physical examination. Key factors to consider include alcohol consumption, medication use, and exposure to hepatotoxic substances. Laboratory investigations should include a complete liver panel, coagulation studies, and serologic tests for viral hepatitis.
Management
Management of ELE primarily focuses on addressing the underlying cause. This may involve lifestyle modifications, medication changes, or specific treatments for identified liver diseases. Close monitoring of liver function tests is essential to assess response to treatment and detect any potential complications.
Role of Imaging
Imaging studies, such as ultrasound or CT scan, can provide valuable information about the liver's structure and help identify conditions such as fatty liver disease or cirrhosis. However, these should be reserved for cases where initial investigations are inconclusive.
Conclusion
Diagnosing and managing ELE requires a systematic approach that includes thorough history taking, appropriate laboratory and imaging investigations, and targeted treatment strategies. By adopting such an approach, clinicians can effectively manage this common clinical dilemma.
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
Depression risk higher among long-term breast cancer survivors than women without breast cancer history
2.
Researchers have determined that malignancy hibernation will be the next front in the fight against breast cancer.
3.
Delaying Pegfilgrastim May Curb Bone Pain in Breast Cancer
4.
A Possible Novel CAR-T Treatment for High-Risk R/R Follicular Lymphoma May Be Liso-Cel.
5.
Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.
1.
Therapeutic Advances in RNA-Based Hematologic Therapies
2.
Cancer Diagnosis in 2025: Innovations, Education, and Evolving Clinical Strategies
3.
Developmental Changes in Pediatric Coagulation Networks
4.
Clinical Guidelines for Tumor Evolution Tracking Using Dynamic Molecular Profiling
5.
Seeing the Unseen: Examining Chancroid Through Images
1.
International Conference on Oncology, Cancer Prevention and Public Health
2.
International Conference on Cancer Nursing and Rehabilitation Strategies
3.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
4.
International Conference on Innovations in Critical Care for Oncology and Cardiology
5.
International Symposium on Oncology, Cardiology and Critical Care Innovations
1.
Current Scenario of Cancer- Q&A Session to Close the Gap
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
4.
Understanding the Importance of Early Cancer Detection
5.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge